---
document_datetime: 2023-09-21 17:08:49
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/onsenal-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: onsenal-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.0692008
conversion_datetime: 2025-12-25 10:12:09.470162
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| No      | Scope                                                                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on affected no   | Product Information 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0028 | Update of Summary of Product Characteristics and Package Leaflet Update of section 4.2 of the SmPC to include patients carrier of the CYP2C9*3 genotype in the existing recommendation on patients with suspected poor metabolism (CYP2C9 genotype carrier). Section 4.5 is updated in relation to concomitant product | 24/06/2010                          | 28/07/2010                                              | SPC, Annex II, PL       | Literature review of clinical PK studies with celecoxib suggests that reduced CYP2C9 activity in patients with one or two *3 alleles may result in reduced celecoxib clearance. This evidence is sparse representing a total of 8 subjects with *3/*3 genotype in four clinical PK studies, with no more than 3 such subjects in any single study. Subjects with the *3/*3 genotype may have increased celecoxib exposures compared to *1/*1 subjects, the difference is not precisely estimated and ranges from 1 to 7 fold. Data for |

●

7 Westferry Circus

Telephone

Canary Wharf

+44 (0)20 7418 8400

E-mail

●

London E14 4HB

Facsimile

●

United Kingdom

<!-- image -->

<!-- image -->

+44 (0) 20 7523 7455 info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Onsenal Procedural steps taken and scientific information after the authorisation Changes made after 1 May 2004 For procedures finalised before 1 May 2004, please refer to 'Procedural steps taken until cut-off date' 1 Notifications are issued for type I variations (unless part of a group or a worksharing application). Opinions are issued for all other procedures. 2 No Commission Decision is issued for type IA and type IB variations or for type II variations and annual re-assessments that do not affect the annexes. 3 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No                             | Scope                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0029 Onsenal EMA/518517/2010 | Annual reassessment Seventh annual reassessment of Onsenal, as the approval was granted under exceptional circumstances. The MAH took the opportunity to update annex II in line with the last QRD template. Medicinal | 18/03/2010 product                  | 17/06/2010 no                               | Annex II longer                  | warning in section 4.4 on cardio-vascular disorder nevertheless for clarification and completeness of the information this event is added to the SmPC with a frequency category of unknown. On the basis of the data submitted since the Marketing Authorisation, the benefit/risk balance in the reduction of the number of adenomatous intestinal polyps in familial polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance, remains positive. The CHMP agreed that the Marketing Authorisation should remain under exceptional circumstances. The CHMP agreed to maintain the specific obligation for the MAH in order to generate further efficacy and safety data by undertaking a Phase III placebo- controlled trial with celecoxib in genotype positive subjects with familial adenomatous polyposis Page 3/12 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

| No        | Scope                                                                                                                                                                                                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0030/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the active substance - Minor change in the manufacturing process of the active substance, B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer. product | 27/04/2010                          | n/a no                                      |                                  | in FAP patients consists of worldwide online questionnaire adverse events FAP patients. The capture information authorised indication celecoxib at any longer |

<!-- image -->

Page 5/12 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0026  | Annual reassessment Sixth annual reassessment of Onsenal, as the approval was granted under exceptional circumstances.                                                                          | 25/06/2009                          | 14/10/2009 no                               | Annex II                         | On the basis of the data submitted since the Marketing Authorisation, the benefit/risk balance in the reduction of the number of Adenomatous intestinal polyps in familial polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance, remains positive. In order to generate further efficacy and safety data, the CHMP agreed to amend the specific obligation to include feasibility for the protocol amendment of the Phase III placebo- controlled trial with celecoxib in genotype positive subjects with familial adenomatous polyposis (A3191193 - CHIP trial). By this, it is expected that the recruitment rate of this trial will be accelerated in order to generate relevant clinical data on this orphan designation. longer |
| IB/0027 | 14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer product                                                                                               | 03/09/2009                          | n/a                                         |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0025 | Update of Summary of Product Characteristics and Package Leaflet Update of Summary of Product Characteristics and Package Leaflet. To harmonise the Summary of Product Characteristics (SPC) of | 22/01/2009                          | 17/03/2009                                  | SPC, PL                          | Sections 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SPC of Onsenal were updated to include data on poor metabolizers and in lactating mothers, hypertension and renal effects, post marketing safety data and final results from the Prevention of Sporadic Colorectal Adenomas with Celecoxib (APC), the Prevention of Colorectal Sporadic Adenomatous Polyps                                                                                                                                                                                                                                                                                                                                                                                     |

<!-- image -->

<!-- image -->

Page 6/12 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

| No                     | Scope                                                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                     |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                        | Onsenal with the SPC of Celebra (version date 14 November 2007) as requested by the CHMP at the time of the opinion on the 4th Annual Re- assessment, with amendment to the sections 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SPC. The Package Leaflet was amended accordingly. |                                     | no                                          | longer                           | (Pre SAP) and the Alzheimer's disease Anti- Inflammatory Prevention (ADAPT) trials. In addition, a specific paragraph for skin reactions was implemented and a warning for cardiovascular risk was added.                                                                                                                                   |
| R/0021                 | Renewal of the marketing authorisation                                                                                                                                                                                                                                                       | 24/07/2008                          | 20/10/2008                                  | Annex II                         |                                                                                                                                                                                                                                                                                                                                             |
| IA/0023                | 09_Deletion of manufacturing site                                                                                                                                                                                                                                                            | 19/06/2008                          | n/a                                         | Annex II, PL                     |                                                                                                                                                                                                                                                                                                                                             |
| IA/0024                | 05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                               | 19/06/2008 product                  | n/a                                         | Annex II, PL                     |                                                                                                                                                                                                                                                                                                                                             |
| S/0020 EMA/518517/2010 | Annual reassessment Fourth annual reassessment of Onsenal, as the approval was granted under exceptional circumstances. Medicinal                                                                                                                                                            | 19/03/2008                          | 20/05/2008                                  | Annex II                         | On the basis of the data submitted since the Marketing Authorisation, the risk/benefit balance in the reduction of the number of adenomatous intestinal polyps in familial polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance, remains positive. The CHMP agreed to change the specific obligation set Page 7/12 |
| Onsenal                | Onsenal                                                                                                                                                                                                                                                                                      | Onsenal                             | Onsenal                                     | Onsenal                          | Onsenal                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------|-------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| T/0014  | Transfer of Marketing Authorisation Holder                                                | 06/12/2007                          | 25/01/2008                                  | SPC, Labelling, PL               | longer    |
| IB/0015 | 14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer | 10/01/2008                          | n/a no                                      |                                  |           |
| IB/0017 | 10_Minor change in the manufacturing process of the active substance product              | 14/11/2007                          | n/a                                         |                                  |           |
| IA/0016 | 09_Deletion of manufacturing site                                                         | 05/11/2007                          | n/a                                         |                                  |           |
| IA/0019 | 22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer          | 31/10/2007                          | n/a                                         |                                  |           |
| IA/0018 | 22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new                       | 31/10/2007                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

Page 8/12 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| No       | Scope                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                            |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------|
|          | manufacturer                                                                                                                                                                                                                         |                                     |                                             |                                  |                                                                    |
| S/0012   | Annual reassessment 3rd Annual-Reasessment                                                                                                                                                                                           | 24/05/2007                          | 25/07/2007                                  | SPC, Labelling, PL               |                                                                    |
| IB/0010  | 10_Minor change in the manufacturing process of the active substance                                                                                                                                                                 | 12/07/2006                          | n/a                                         |                                  | longer                                                             |
| IA/0011  | 08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing                                                                                                                                            | 29/06/2006                          | n/a no                                      | Annex II, Labelling, PL          |                                                                    |
| IA/0008  | 09_Deletion of manufacturing site                                                                                                                                                                                                    | 02/06/2006                          | n/a                                         |                                  |                                                                    |
| IA/0007  | 05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                       | 02/06/2006 product                  | n/a                                         |                                  |                                                                    |
| A18/0005 | Article 18 Review Further to a request from the European Commission to review the cardiovascular safety and the serious skin reactions of medicinal products containing celecoxib, etoricoxib, lumiracoxib, parecoxib or valdecoxib. | 23/06/2005                          | 05/10/2005                                  | SPC, PL                          | Please refer to the scientific discussion: Onsenal-H- 466-Art18-05 |

<!-- image -->

<!-- image -->

Page 9/12 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|---------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                                                                                 |                                     | no                                          |                                  | exercise caution when prescribing NSAIDs, including celecoxib, in combination with ACE inhibitors or angiotensin II receptor antagonists. · Information on long-term studies for celecoxib in SAP and Alzheimer's disesase has been included. On the basis of the data submitted since the Marketing Authorisation, the risk/benefit in the reduction of the number of adenomatous intestinal polyps in familial polyposis (FAP), as and adjunct to surgery and further endoscopic surveillance, remains positive. The CHMP agreed that the Marketing Authorisation should remain under exceptional circumstances. longer |
| IB/0003 | 42_a_01_Change in shelf-life of finished product - as packaged for sale product | 10/11/2004                          | n/a                                         | SPC                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0002 | 01_Change in the name and/or address of the marketing authorisation holder      | 28/06/2004                          | n/a                                         | SPC, Labelling, PL               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<!-- image -->